Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina.
| Revenue (Most Recent Fiscal Year) | $68.70M |
| Net Income (Most Recent Fiscal Year) | $7.17M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.07 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.05 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -42.99% |
| Net Margin (Trailing 12 Months) | -42.99% |
| Return on Equity (Trailing 12 Months) | -69.26% |
| Return on Assets (Trailing 12 Months) | -29.30% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.62 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.62 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.45 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.45 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.21 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.26 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 11.09M |
| Free Float | 10.59M |
| Market Capitalization | $54.55M |
| Average Volume (Last 20 Days) | 0.07M |
| Beta (Past 60 Months) | 1.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 37.99% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |